Navigation Links
Scientists developing new therapy for HER2-positive breast cancer
Date:7/26/2011

PHILADELPHIA Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Jacek Capala, Ph.D., D.Sc., an investigator at the National Cancer Institute, and colleagues designed, produced and tested HER2-Affitoxin, a novel protein that combines HER2-specific affibody molecules and a modified bacterial toxin, PE38.

"Unlike the current HER2-targeted therapeutics, such as Herceptin, this protein does not interfere with the HER2 signaling pathway but, instead, uses HER2 as a target to deliver a modified form of bacterial toxin specifically to the HER2-positive cancer cells. When cells absorb the toxin, it interferes with protein production and, thereby, kills them," said Capala.

At least, that is what happened in Capala's laboratory. After Affitoxin was injected into tumor-bearing mice, even relatively large, aggressive tumors stopped growing and most of them disappeared. The effect was strong enough that Capala believes it warrants a clinical trial.

"Herceptin has revolutionized the treatment of patients with HER2-positive breast cancer, but a significant number of tumors acquire resistance to the drug," said Capala. "Affitoxin could offer another therapeutic option for those patients whose tumors no longer respond to Herceptin."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer
2. Scientists Close in on Origins of Psoriasis, Eczema
3. Hebrew U. scientists identify molecular basis for DNA breakage
4. Scientists Spot Possible Target in Ovarian Cancer
5. 7 in 1 blow: Scientists discover DNA regions influencing prostate cancer risk
6. Gold nanoparticles bring scientists closer to a treatment for cancer
7. Scientists identify order of mutations that lead to cancer
8. Scientists discover new molecular pathway involved in wound-healing and temperature sensation
9. Neuroscientists find famous optical illusion surprisingly potent
10. Scientists sequence endangered Tasmanian devils genome
11. Scientists identify a novel mechanism for evolution of highly aggressive cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: